Journal News

Does a protein hold the key to Alzheimer’s?

Jay Thakkar
Dec. 10, 2024

Alzheimer’s disease, or AD, is the best-known neurodegenerative disorder affecting cognitive functioning and accounts for 60% to 80% of dementia cases. Understanding the progression of AD is relevant for its treatment, and multiple hypotheses exist to explain how the disease progresses.

One of these is the tau hypothesis; tau is a protein that stabilizes microtubules, an important component in neurons. Misfolding of tau leads to its aggregation in cells. This accumulation of tau starts spreading throughout the brain of AD patients by moving from cell to cell.

In a recent study published in the Journal of Biological Chemistry, Joanna Cooper at the University of Maryland School of Medicine, Aurelien Lathuiliere at Massachusetts General Hospital and a team of researchers focused on a receptor called Sortilin-related receptor 1, or SORL1, that is involved in tau accumulation inside the cells.

“SORL1 has been associated with Alzheimer’s disease in a sense that mutations have been found that may be causative, but there is no consensus as to how that is working,” Cooper said. “Most research previously has focused on its role with amyloid beta, which is the other main player in Alzheimer’s disease.”

Prior research showed that lower levels of SORL1 increase the generation of a polypeptide called amyloid beta, the main component of amyloid plaque found in AD patients. This new research indicates SORL1 increases tau seeding, highlighting a contradiction in the role of SORL1 in AD progression.

“I think it’s a new line of research with the potential to have translational implications for patients,” Lathuiliere said.

With amyloid beta, loss of function of SORL1 is problematic, whereas in the context of tau there might also be a gain of toxic function, Cooper explained. “That adds a whole dichotomy into thinking about what SORL1 does,” she said.

Researchers need to do more work in the lab to determine if SORL1 is a therapeutically relevant target for AD patients.

“It was really easy to identify that it acts as a direct binding partner to tau,” Cooper said. That simple experiment quickly gave conclusive results.

 “It was a lot more challenging to dig into what can SORL1 do and try to understand something that gives us insight it’s actual physiological function.”

The team used surface plasmon resonance to detect the binding affinity of SORL1 with tau. They conducted immunofluorescence staining and Förster resonance energy transfer assays to understand where tau was positioned among cells and to understand the implication of specific SORL1 mutations in AD patients.

Even if SORL1 isn’t targeted directly for therapeutics, this finding “provides context for the machinery that is helping to traffic tau and opens up a lot more understanding about how that process happens,” Cooper said.

Overall, tau seeding causes AD to progress. Understanding where tau is within and among cells and the receptors responsible for cellular uptake and transport will help researchers explore avenues for treating AD.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Jay Thakkar

Jay Thakkar is a researcher, who specializes in computer-aided drug design and discovery. He earned a bachelor's degree in chemical engineering from the Dwarkadas J. Sanghvi College of Engineering in Mumbai, India, and a master's degree in chemistry from the Stevens Institute of Technology in Hoboken, New Jersey, where he studied drug discovery. His hobbies include reading, driving on open roads and walking in the park.
 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Understanding the roles of extracellular matrix and vesicles in valvular disease
Profile

Understanding the roles of extracellular matrix and vesicles in valvular disease

Oct. 30, 2025

MOSAIC scholar Cassandra Clift uses mass spectrometry and multiomics to study cardiovascular calcification and collagen dysregulation, bridging her background in bioengineering and biology to investigate extracellular vesicles and heart disease.

Lipid profiles reveal sex differences in type 2 diabetes
Journal News

Lipid profiles reveal sex differences in type 2 diabetes

Oct. 29, 2025

Researchers explored the lipid profiles of individuals with type 2 diabetes and identified potentially useful lipid biomarkers for this condition.

Serum lipids may predict early diabetes risk
Journal News

Serum lipids may predict early diabetes risk

Oct. 29, 2025

Researchers found that levels of two key fatty acids may predict worsening tolerance for glucose, independent of body fat and insulin levels. In turn, these fatty acids may serve as early T2D biomarkers.

Sex and diet shape fat tissue lipid profiles in obesity
Journal News

Sex and diet shape fat tissue lipid profiles in obesity

Oct. 29, 2025

Researchers found that sex hormone levels and diet both influence inflammation and lipid composition in obesity.

Mapping the placenta’s hormone network
Journal News

Mapping the placenta’s hormone network

Oct. 21, 2025

Study uncovers how the placenta actively metabolizes not only glucocorticoids but also novel androgens and progesterones, reshaping our understanding of pregnancy and its complications.

Biochemists and molecular biologists sweep major 2025 honors
News

Biochemists and molecular biologists sweep major 2025 honors

Oct. 20, 2025

Recent Nobel, MacArthur and Kimberly Prize honorees highlight the power of biochemistry and molecular biology to drive discovery, including immune tolerance, vaccine design and metabolic disease, and to advance medicine and improve human health.